JASPER THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
JASPER THERAPEUTICS, INC. (JSPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $500.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-30
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $0.00.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $100.00K, a 0.00% change year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $100.00K, a 75.00% decline year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $400.00K, a 300.00% increase year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $500.00K, a 25.00% increase from fiscal 2023.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $400.00K, a 300.00% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $100.00K derived: sum of 2 quarters · filed 2026-03-30 | $200.00K derived: sum of 3 quarters · filed 2026-03-30 | $500.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-10 | $200.00K derived: sum of 2 quarters · filed 2025-11-10 | $500.00K 10-Q · filed 2025-11-10 | $600.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-13 | $500.00K 10-Q · filed 2025-08-13 | $500.00K derived: sum of 3 quarters · filed 2025-08-13 | $600.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $400.00K 10-Q · filed 2025-05-12 | $400.00K derived: sum of 2 quarters · filed 2025-05-12 | $500.00K derived: sum of 3 quarters · filed 2025-05-12 | $900.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $100.00K derived: sum of 2 quarters · filed 2025-02-28 | $500.00K derived: sum of 3 quarters · filed 2025-02-28 | $400.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-07 | $500.00K derived: sum of 2 quarters · filed 2024-11-07 | $400.00K 10-Q · filed 2024-11-07 | $600.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-13 | $400.00K 10-Q · filed 2024-08-13 | $500.00K derived: sum of 3 quarters · filed 2024-08-13 | $600.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-14 | $100.00K derived: sum of 2 quarters · filed 2024-05-14 | $200.00K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $100.00K derived: sum of 2 quarters · filed 2024-03-05 | $100.00K 10-K · filed 2024-03-05 | |
| 2022-09-30 | $100.00K 10-Q · filed 2023-11-09 | $100.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |